There is no FDA-approved generic version of Ozempic available in the United States. The active ingredient, semaglutide, is protected by patents that aren’t expected to expire in the U.S. until at least 2032. What you’ll find marketed online as “generic Ozempic” is almost always a compounded version of semaglutide, which is a fundamentally different product with different oversight, different risks, and a very different price tag.
Why No Generic Exists Yet
For a true generic drug to reach the U.S. market, it must receive FDA approval under a process that requires the manufacturer to prove the product is therapeutically equivalent to the brand-name drug. That process can’t begin in earnest until the original patents expire. Novo Nordisk, the maker of Ozempic, holds patent protection on semaglutide through at least 2032 in the United States.
The situation is different internationally. In Canada, the semaglutide patent has already lapsed, and at least one company has filed for approval to launch a generic there, potentially as early as 2026. In India, Sun Pharmaceutical received government approval in early 2026 to manufacture and market generic semaglutide injections under new brand names. But none of these international generics are legally sold in the U.S.
Compounded Semaglutide Is Not a Generic
The products you see advertised at a fraction of Ozempic’s price are compounded versions of semaglutide. Compounding means a pharmacy mixes the drug from bulk ingredients, typically to fill a specific prescription. This is legal under certain conditions, but the distinction from a true generic matters enormously: compounded drugs are not FDA-approved. The FDA does not verify their safety, effectiveness, or quality before they reach patients.
A true generic goes through rigorous FDA review to confirm it delivers the same active ingredient in the same way as the brand-name product. A compounded drug skips that entire process. The FDA has explicitly warned companies against calling compounded semaglutide “the generic drug delivered in Ozempic,” issuing warning letters to businesses making that exact claim and labeling it false and misleading.
How Compounding Pharmacies Are Regulated
Not all compounding pharmacies operate under the same rules. The FDA recognizes two categories. Section 503A pharmacies are traditional state-licensed pharmacies that compound medications for individual patients based on specific prescriptions. They follow pharmacy standards but are not required to follow the same manufacturing practices as drug companies. Section 503B pharmacies, called outsourcing facilities, can produce larger batches and are held to stricter federal manufacturing standards. They must maintain an independent quality department, register with the FDA, validate every production process, and report their product lists twice a year.
If you’re considering compounded semaglutide, the type of pharmacy it comes from affects the level of quality oversight your product received. A 503B outsourcing facility operates closer to pharmaceutical manufacturing standards than a traditional compounding pharmacy does.
Safety Concerns With Compounded Versions
The FDA has flagged several specific risks. As of July 2025, the agency had received 605 reports of adverse events associated with compounded semaglutide, including nausea, vomiting, diarrhea, abdominal pain, and constipation. Some of these events were serious enough to require hospitalization, and the FDA has linked many of them to dosing errors with compounded injectable products.
There’s also a chemical concern. Some compounders use salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate, rather than the base form used in FDA-approved Ozempic. The FDA says these are technically different active ingredients. The agency has no data confirming whether these salt forms behave the same way in the body, and it is not aware of any lawful basis for using them in compounding.
The Shortage That Opened the Door
Compounded semaglutide became widely available because of a loophole tied to drug shortages. Semaglutide injection products were on the FDA’s official shortage list from 2022 through early 2025, driven by surging demand. During a shortage, compounding pharmacies are permitted to make copies of FDA-approved drugs they normally couldn’t.
In February 2025, the FDA declared the semaglutide shortage resolved. The agency gave 503A pharmacies until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to wind down production. After those dates, compounding semaglutide as a copy of an FDA-approved product returned to its usual restricted legal status. Some compounders have challenged these deadlines in court, so the legal landscape continues to shift.
Cost Differences
The price gap is the main reason people seek out compounded semaglutide. Brand-name Ozempic runs $1,200 to $1,500 per month without insurance. Compounded versions typically cost $200 to $400 per month, depending on the pharmacy and provider.
Insurance adds another layer of complexity. Most insurance plans cover Ozempic only for its FDA-approved use in type 2 diabetes, not for weight loss. Compounded versions are generally not covered by insurance at all, which means you’re paying out of pocket either way if your goal is weight management. For people with diabetes and qualifying insurance, brand-name Ozempic may actually end up costing less after coverage than a compounded version would.
What to Know Before Choosing
If you see a product marketed as “generic Ozempic” in the U.S., it is not a generic in any FDA-recognized sense. It is either a compounded product or, in some cases, a counterfeit. The distinction matters because compounded products carry real risks: inconsistent dosing, unverified active ingredients, and no FDA review of safety or effectiveness before they reach you.
That said, compounded medications serve a legitimate role in medicine, particularly when commercial products aren’t available or when patients need customized dosing. The key is understanding what you’re actually buying. A true generic semaglutide in the U.S. is likely still years away. Until then, the choice is between the FDA-approved brand-name products and compounded alternatives that come with meaningful trade-offs in cost, oversight, and risk.